Pfizer (PFE) Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Pfizer+%28PFE%29+Announces+Positive+Top-Line+Results+from+Phase+3+Study+of+ABRYSVO+in+Adults+Aged+18+to+59+at+Increased+Risk+for+RSV+Disease/23043070.html for the full story.